A case series of patients, including a consultant rhinologist, who all experienced a loss of smell associated with confirmed or suspected COVID-19*

David E.J. Whitehead1, Christine Kelly2, N. Ahmad1

1 Department of Otorhinolaryngology, James Cook University Hospital, Middlesbrough, United Kingdom
2 AbScent, 14 London Road, Andover, Hampshire, United Kingdom

Abstract

**Background:** Non-invasive detection of carriers of COVID-19 virus remains elusive. A decrease in sense of smell appears to be a potential marker of the disease. However, it is not the most frequently reported complaint and there may be more novel early markers of disease.

**Methodology:** We present a case series of patients, including a consultant rhinologist who all experienced a loss of smell associated with confirmed or suspected COVID-19.

**Results:** A consultant rhinologist presented with a delayed sudden onset anosmia, four days after testing positive for coronavirus whilst also exhibiting evidence of autonomic dysfunction prior to rRT-PCR diagnosis and during the time period during which smell suddenly deteriorated. Sudden loss of smell can occur within a 3-hour window and a transient increase in SNOT-22 score was also noted at the time of loss.

**Conclusions:** Transient hyposmia or anosmia appear to be an early warning sign or marker symptom associated with COVID-19. Smell can be lost rapidly but appears to recover for many. For others a variety of novel treatments exist. There may be more sensitive or specific signs associated with the disease.

**Key words:** anosmia, autonomic dysfunction, autonomic nervous system, coronavirus, COVID-19, heart rate variability, hyposmia, olfactory loss, smell training, SNOT-22

Introduction

**Case report 1**
A 49-year old Rhinologist (the first author) developed a mild cough, rigors and a pyrexia of 40.2°C following a week on-call operating on multiple suspected COVID-19 patients (wearing Personal Protective Equipment, PPE). Two days after becoming symptomatic real-time reverse transcription polymerase chain reaction (rRT-PCR) testing confirmed he was positive for COVID-19. Four days after noticing symptoms he developed a mild nasal congestion and rhinorrhea.

His sense of smell was normal, and he continued to improve until 7 days after developing his first symptoms when at 15:35hrs he noticed a headache and hyposmia1. At 17:03hrs 90% of his sense of smell had been subjectively lost and congestion confined to high up in the nasal vault (cavity) was reported as a symptom2, with no turbinate congestion. At 18:30hrs his temperature rose to 38.6°C and complete anosmia was noted. There was some associated sneezing and his NOSE score at that point was 3 and his SNOT-22 score was 33.

At 23:20hrs he developed complete nasal blockage on the left side and rhinorrhea affecting the right nasal cavity. He developed bilateral ear congestion and a burning sensation in the postnasal space similar to that experienced by the author many decades before when he had adenovirus.
A 21-year old female student incidentally noticed a complete acute loss of sense of smell while preparing a barbeque. Two days later she developed headache, nasal congestion, chest tightness, a mild cough, as well as fatigue and light-headedness. Her nasal congestion continued for 2 weeks and the headache worsened until day 3 when she also experienced rigors. She had partially recovered with an UPSIT score of 27 (which is moderate microsmia adjusted for age). Six days after complete anosmia a retest using the UPSIT showed a score of 27. Six weeks following anosmia UPSIT score was 39 and within the 90th percentile adjusted for the age.

**Case report 2**

A 50-year old female had a minor procedure and the next day she noticed symptoms of mild rhinitis and her husband became unwell with symptoms of coronavirus. The following day she noticed an increased tolerance to Capsaicin in chilli peppers and freshly ground black pepper. Its effect was reduced and confined only to the oral cavity. A trial of 0.1 % Xylometazoline Hydrochloride nasal spray had no effect on subjective smell perception.

Four days following the sudden onset of anosmia, his smell had partially recovered with an UPSIT score of 27 (which is moderate microsmia adjusted for age). Six days after complete anosmia a retest using the UPSIT showed a score of 27. Six weeks following anosmia UPSIT score was 39 and within the 90th percentile adjusted for the age.

**Case report 3**

A 50-year old female woke with a unilateral “migraine,” nausea and complete anosmia but no loss of taste sensation, instead noticing increased sensitivity to salt and vinegar. This was the worst migraine she had ever experienced and her symptoms worsened until day 3 when she also experienced rigors. She remained in bed and could not eat without vomiting. She did not experience nasal congestion but felt lightheaded on day 4 and 5. Her sense of smell started to return on day 6.

**Case report 4**

On day 8 at 07:44hrs he could barely smell lemon Verbena in hand soap and grapefruit in facial wash. Subjectively, he had lost 98% of his sense of smell. At 12:16hrs, 5% of his smell had returned. His NOSE score had dropped to 1 and the SNOT-22 score had dropped to 8. At 22:24hrs the NOSE score was 0 and SNOT-22 was 9. By day 9 his NOSE score was =0 and SNOT-22 = 12. A heat map of all SNOT-22 scores is shown in Figure 1.

He noticed an increased tolerance to Capsaicin in chilli peppers and freshly ground black pepper. Its effect was reduced and confined only to the oral cavity. A trial of 0.1 % Xylometazoline Hydrochloride nasal spray had no effect on subjective smell perception.

Sweet foods or liquids.

**Other evidence of infection**

Confirmation of active COVID-19 virus depends on a positive real-time reverse transcription polymerase chain reaction (rRT-PCR) test. Technical issues related to obtaining representative viral sampling within 72 hours of onset of symptoms can lead to false negatives. Alternative machine learning methods may provide a non-invasive and less time critical method, a “synthetic test” of predicting who may have COVID-19. ZOE Global Ltd a nutritional science company and King’s College London data scientists have created a model to predict COVID-19 in the UK. Of people who were definitely infected with coronavirus, 59% reported losing their sense of smell or taste. Of people not yet tested, the model predicted 13% are likely to be infected.

Heart rate variability (HRV) represents a non-invasive method of looking at autonomic activity and physiological status of the human body. Several studies have examined the usefulness of HRV for the early diagnosis and prognosis of viral infections.

Wearable technology that continuously measures HRV is widely available from a number of sources (Firstbeat Technologies Oy, Yliopistonkatu 28 A, FI-40100 Jyväskylä, Finland; Garmin Ltd. Liberty House Hounsdown Business Park, Southampton SO40 9LR, UK; WHOOP, Inc., 1325 Boylston Street, Suite 401, Boston, MA 02215, USA and EliteHRV). The first author recorded HRV and ‘stress levels’ during the onset of first symptom and prior to rRT-PCR testing. When smell was lost seen in Figure 2, a significant increase in stress levels (due to a drop in HRV) compared to the patient’s normal stress levels of between 19-25 was observed. The patients average stress level can be seen over a longer time period superimposed onto the above Figure 2. This raises the possibility of integrating consumer wearable analytics into the machine learning methodology developed at King’s College thereby refining the diagnostic model.

**Aetiology**

The reasons why some patients are susceptible to a loss of smell after viral infection is unclear and the precise mechanism of olfactory loss remains elusive. However, two main theories exist, conductive and sensorineural. A conductive loss has also been described as the olfactory cleft syndrome and includes inflammation and obstruction impeding transport. Sensorineural causes include damage or death of sensory cells which could also, confusingly, be caused by their inflammation. Respiratory viruses cause inflammation and resulting oedema of the nasal mucosa, possibly leading to cellular destruction. A history of fluctuating olfactory loss favours a conductive aetiology such as mucosal swelling of the olfactory cleft, which results in a conductive post viral olfactory loss.
Current techniques for detecting olfactory loss can reliably determine the degree of loss but cannot distinguish between conductive or sensorineural aetiology. A variety of quantitative psychophysical tests (12) are available to quantify changes in olfaction.

Viral infections cause varying degrees of olfactory epithelial destruction. The sensory neurones seem to be selectively affected with preservation of supporting cells. Where damage or death of olfactory receptor cells occur, regeneration should occur and may explain the transient sensory loss. Recovery is by no means guaranteed, some will have a persistent smell dysfunction. Where smell does return it will often return within 3 weeks (13).

There are no established treatments available at this time to enhance olfactory epithelial regeneration although a number of novel therapies show promise and have been proposed.

### Tracking

A variety of different software platforms have been rapidly developed and are providing insights not previously available regarding both COVID-19, smell and taste. One of the most successful has been the COVID symptom tracker app (14) developed by King’s College, London in association with Guy’s and St.Thomas’ NHS Foundation trust, NIHR Biomedical Research Centre and a healthcare start-up (ZOE Global Ltd). The American Academy of Otolaryngology has developed the COVID-19 Anosmia Reporting Tool (15) and SmellTracker (16) are others.

The first author used the Nasal Obstructive Symptom Evaluation (17) (NOSE) score, to document obstructive symptoms and the Sino-nasal Outcome Test (SNOT-22) (18) questionnaire to document symptoms as he developed anosmia. Although not validated for this purpose, insights can be gained regarding the COVID-19 related anosmia from a heat map image of sequential SNOT-22 scores (Figure 1).

There has been no study to date about the effect of immediate treatment of post viral olfactory loss (11). It is unknown whether high dose steroids and antiviral medication would be beneficial following the viral insult as patients rarely present early on (9).

### Treatments

There has been no study to date about the effect of immediate treatment of post viral olfactory loss (11). It is unknown whether high dose steroids and antiviral medication would be beneficial following the viral insult as patients rarely present early on (9).

Smell training

It is considered as the most promising non-invasive therapeutic option for various types of smell loss although these changes might also reflect a regression to the mean.

A number of studies have suggested that smell training, i.e. sniffing four different odours; often one flowery, fruity, spicy and resinous (twice a day for 4 to 6 months) is an easy self-driven therapy with no significant side-effects. A meta-analysis showed the strong and statistically significant positive benefit of olfactory training (20). A misunderstanding prevalent among those smell training is that if there is no perception after sniffing, there is no point in the exercise. The action of sniffing and smelling appear to activate regions of the cerebellum and may contribute to the recovery process. The development of the olfactory training ball (21) appears to provide better adherence to the training process. In those who are recovering, it can take time to receive and consider a smell. Patients should be encouraged not to dismiss smells if they cannot initially recognise them. All these comments are based on what we know about smell training and post-viral smell loss pre COVID-19. It remains to be seen whether they are applicable to COVID-19 patients.
The use of bimodal odorants, stimulating olfaction and the trigeminal shows promise (22). Several studies have found changes in central processing of trigeminal stimuli after olfactory loss, reflecting the close interrelationship of these two sensory systems. Loss of sense of smell also leads to changes in the processing of trigeminal stimuli (20). Of note, the first author noticed an increase in tolerance to Capsaicin following the onset of anosmia.

Smell training and corticosteroids

A randomised controlled trial, adding budesonide irrigation to smell training, significantly improved olfactory ability compared with olfactory training plus saline irrigation (24). A randomised controlled trial placing Gelfoam dressing at the olfactory cleft, with or without local administration of 10mg triamcinolone showed that triamcinolone helped restore olfactory function after sinus surgery (25).

Oral and topical corticosteroids

A brief course of oral steroid therapy can aid in determining whether inflammation (causing conductive loss) is the major determining factor of olfactory dysfunction but long term systemic steroid therapy is ill advised and may contribute to immunosuppression during active COVID-19 which we could not recommend.

Omega-3

Omega-3 has anti-inflammatory properties and promotes neuroprotection. A multi-institutional, prospective, randomised controlled trial (26) compared nasal saline irrigation to nasal saline irrigation with 2000mg omega-3 supplementation following endoscopic resection of sellar or parasellar tumours. At 3 and 6 months, patients who had receiving omega-3 demonstrated significantly less persistent olfactory loss compared to patients without supplementation. After controlling for multiple confounding variables, omega-3 supplementation was found to be protective against olfactory loss. Although not directly comparable to post viral olfactory loss, this study may provide a possible area of future research and an ongoing trial of omega-3 in ICU is currently underway to treat COVID-19.

Alpha-lipoic acid

α-Lipoic acid (ALA) has been used to treat diabetic neuropathies with some effectiveness at higher concentrations of 600mg/day. In a nonblinded trial with no controls, the a range of effects of ALA on the olfactory function of 23 patients suffering from post-viral anosmia was demonstrated (27). No other study has supported this study’s findings.
Nasal probiotic
Oral probiotics have been shown to provide a modest but significant effect on the innate inflammatory response and on decreasing viral shedding and viral load in nasal washes following infection (26). Intranasal administration of probiotics (such as PROBIORINSE™) is a future area of research with regard to protecting olfaction (28).

Prognosis /Recovery
Cain reported olfactory loss in 18.6% of patients after viral URTI (18). Very few studies have looked at the prognosis of post viral olfactory dysfunction (31). Unexpectedly, 86% of patients with post viral olfactory loss reported subjective improvement and UPSIT scores improved in 90% (31). Recovery to normosmia was most frequent in patients with mild to moderate hyposmia. Jafek et al. reported that recovery of smell should occur within 3 weeks (19). The first author repeated olfactory testing 6 weeks after total anosmia was noted. Smell had returned to normosmia with a UPSIT score of 39 within the 90th percentile. Although a case report it provides evidence that smell function can return to expected levels for age after the olfactory system has received an insult from COVID-19.

Conclusions and recommendations
A loss of taste and smell as well as autonomic dysfunction appear to be early warning markers of COVID-19 infection (22), but fever and coughing are frequently also present. Loss of sense of smell and taste, when combined with other symptoms, continues to make it likely that an individual has contracted COVID-19.

Wearable consumer technology that records HRV may provide an early non-invasive diagnosis of viral infections in advance of the loss of sense of smell. Recovery from anosmia is likely to begin within 3 weeks of initial loss and can recover completely to within normal age adjusted ranges within 6 weeks. Smell training with bimodal odors (22) (stimulating both olfaction and trigeminal systems) with the addition of budesonide irrigation appears to offer the most promise for future research. Omega-3 supplementation may confer an additional benefit and the contribution of topical steroids placed within the nose such as PROPEL™ & SINUVA® as early adjunctive therapy to aid recovery should be studied though randomised controlled trials.

Acknowledgments
None.

Authorship contribution
DW wrote the manuscript and provided case data. CK provided data regarding smell training and edited the manuscript, NA edited the manuscript.

Conflict of interest
CK is the founder of AbScent, a charity registered in England and Wales No. 1183468, that supports people with smell loss.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and materials
Not applicable.

Funding
Not applicable.

References

David E.J. Whitehead
Department of Otorhinolaryngology
James Cook University Hospital
Middlesbrough, TS4 3BW
United Kingdom
E-mail: david@ent.org.uk

ISSN: 2589-5613 / ©2020 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/